Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

st marys medical park pharmacy - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 20 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in using enalapril maleate consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see warnings, neutropenia/agranulocytosis ). in considering use of enalapril maleate, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. do not coadminister aliskiren with enalapril maleate in patients with diabetes (see precautions, drug interactions ). enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings, head and neck angioedema ).

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

greenstone llc - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 2 mg - trandolapril/verapamil hydrochloride er tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using trandolapril/verapamil hydrochloride er tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). trandolapril/verapamil hydrochloride er tablets are contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, trandolapril/verapamil hydrochloride er tablets are contraindicated in: - severe left ventricular dysfunction (see warnings ). - hypotension (systolic pressure less than 90 mmhg) or cardiogenic shock. - sick sinus syndrome (exce

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: head and neck angioedema). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. enalapril maleate and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ). do not co-administer aliskiren with enalapril maleate and hydrochlorothiazide in patients with diabetes (see precautions, drug interactions ).

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

dr. reddy's laboratories limited - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angi

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, usp, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings , head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

physicians total care, inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 g - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - enalaprilat dihydrate (unii: gv0o7es0r3) (enalaprilat anhydrous - unii:q508q118jm) - enalaprilat 1.25 mg in 1 ml - enalaprilat injection, usp is indicated for the treatment of hypertension when oral therapy is not practical. enalaprilat injection, usp has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. in using enalaprilat injection, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection, usp does not have a similar risk. (see warnings.) in considering use of enalaprilat injection, usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (see warnings, angioedema ). enalaprilat injection, usp is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

Armenien - Englisch - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

replek farm ltd.-skopje - enalapril (enalapril maleate) - tablets - 5mg